dronabinol (Starton Therapeutics/Transdermal Research Pharm Laboratories)

N/A

Report date: 2025/08/19 16:10:55

Base Information

Drug Namedronabinol (Starton Therapeutics/Transdermal Research Pharm Laboratories)
Drug Alias Namecannabinoid receptors agonist (ChemioCare/Transdermal Research Pharm Laboratories)dronabinol (ChemioCare/Transdermal Research Pharm Laboratories)delta-9-tetrahydrocannabinol (ChemioCare/Transdermal Research Pharm Laboratories)synthetic cannabinoid (ChemioCare/Transdermal Research Pharm Laboratories)CMIO-DRONAB +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB1 receptor agonistsCannabinoid CB2 receptor agonists
TargetsCannabinoid CB2 receptorCannabinoid CB1 receptor
Therapy Area/IndicationsChemotherapy-induced nausea and vomiting
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesStarton Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTransdermal Research Pharm Laboratories LlcStarton Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsChemotherapy-induced nausea and vomiting
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A